Bicara Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update
Research and development spending increased as pivotal and alternate-dosing trials continued; existing funds are expected to last into the first half of 2029.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Bicara Therapeutics (Nasdaq: BCAX) reported a wider third-quarter 2026 net loss while advancing its pivotal trial of ficerafusp alfa.
Net loss was $71.2 million, compared with $36.3 million a year earlier. Research and development expenses rose to $56.5 million from $33.0 million; general and administrative expenses increased to $19.2 million from $7.7 million. Cash, cash equivalents and marketable securities totaled $442.3 million at September 30, versus $414.8 million at December 31, 2025. Bicara expects these funds to support operations into the first half of 2029.
FORTIFI-HN01 achieved substantial enrollment in first-line recurrent or metastatic HPV-negative head and neck cancer, with interim topline results expected in mid-2027. FORTIFI-FLEX continues enrolling to evaluate less-frequent dosing. Bicara expects its results by potential U.S. approval and plans colorectal cancer expansion-cohort data in January 2027.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Hollow bars mark forward-looking points. How the balance works
Positive
- Moderate point. Forward-looking: it has not happened yet and may not happen.Existing funds are expected to support operations into the first half of 2029 under current plans.
- Moderate point. Forward-looking: it has not happened yet and may not happen.FORTIFI-HN01 achieved substantial enrollment; Bicara expects pivotal-trial interim topline results in mid-2027.
- Minor pointCash, cash equivalents and marketable securities increased to $442.3 million at September 30 from $414.8 million at year-end 2025.
- Minor point. Forward-looking: it has not happened yet and may not happen.FORTIFI-FLEX continues enrolling; Bicara expects alternate-dosing results by potential U.S. approval in first-line HPV-negative head and neck cancer.
- Minor point. Forward-looking: it has not happened yet and may not happen.Phase 1b colorectal cancer expansion-cohort data are planned for January 2027, evaluating monotherapy and combination treatment.
2 minor points
- Minor point. Forward-looking: it has not happened yet and may not happen.Preclinical fibrosis and drug-penetration data are planned for presentation December 14–16, 2026.
- Minor pointThird-quarter interest income rose to $4.516 million from $4.386 million a year earlier.
Negative
- Moderate pointThird-quarter net loss widened to $71.249 million from $36.330 million a year earlier.
- Minor pointThird-quarter basic and diluted loss per share widened to $1.04 from $0.67 a year earlier.
- Minor pointThird-quarter research and development expenses rose to $56.476 million from $32.975 million a year earlier.
- Minor pointThird-quarter general and administrative expenses rose to $19.235 million from $7.701 million a year earlier.
- Minor pointNine-month net loss widened to $182.896 million from $100.564 million a year earlier.
5 minor points
- Minor pointNine-month basic and diluted loss per share widened to $2.78 from $1.84 a year earlier.
- Minor pointNine-month research and development expenses increased to $149.713 million from $92.106 million a year earlier.
- Minor pointNine-month general and administrative expenses increased to $46.190 million from $22.376 million a year earlier.
- Minor pointNine-month interest income declined to $13.175 million from $14.082 million a year earlier.
- Minor pointTotal liabilities increased to $51.231 million at September 30, 2026, from $29.542 million at year-end 2025.
Key Figures
- Cash, cash equivalents and marketable securities
- $442.3 million
- As of September 30, 2026; compared with $414.8 million as of December 31, 2025
- Cash runway
- Into the first half of 2029
- Based on current operating and development plans
- FORTIFI-HN01 interim analysis
- Mid-2027
- Expected timing for topline results
- FORTIFI-FLEX dosing regimens
- 1500 mg weekly for 12 weeks, then 2250 mg every three weeks; comparator: 1500 mg weekly
- Ficerafusp alfa regimens evaluated in combination with pembrolizumab
- Research and development expenses
- $56.5 million
- Third quarter 2026; compared with $33.0 million in third quarter 2025
- General and administrative expenses
- $19.2 million
- Third quarter 2026; compared with $7.7 million in third quarter 2025
- Net loss
- $71.2 million
- Third quarter 2026; compared with $36.3 million in third quarter 2025
Previous Earnings Reports
-
FORTIFI-HN01 enrollment remained on track for a mid-2027 interim analysis; runway extended into H1 2029.
-
FORTIFI-HN01 Phase 3 began with a mid-2027 interim analysis planned; cash runway extended into H1 2029.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
tgf-β medical
hnscc medical
monoclonal antibody medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
Achieved substantial enrollment in FORTIFI-HN01 pivotal trial in 1L R/M HPV-negative HNSCC; topline results from interim analysis expected in mid-2027
Enrolling FORTIFI-FLEX alternate dosing study; expect to have data by the time of potential U.S. approval in 1L R/M HPV-negative HNSCC
Company to host conference call and webcast today, November 9, 2026 at 8:30 a.m. ET
BOSTON, Nov. 09, 2026 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors, today announced financial results for the third quarter ended September 30, 2026 and provided a business update.
“Ficerafusp alfa was purpose-built for HPV-negative head and neck cancer by inhibiting both EGFR and TGF-β, and the depth and durability of response it has demonstrated to date continue to set it apart in a disease with significant unmet need,” said Ryan Cohlhepp, President, Interim Chief Executive Officer and Chief Operating Officer of Bicara Therapeutics. “Achieving substantial enrollment in the FORTIFI-HN01 pivotal trial reflects strong execution by our team and growing recognition among investigators that HPV-negative disease requires a targeted approach grounded in its distinct biology. As we advance toward our planned interim analysis, our focus is twofold: moving with speed and aiming for ficerafusp alfa to enter the market with a competitive profile that gives physicians, patients, and payers a clear reason to choose it. At the same time, we are evaluating less-frequent dosing through FORTIFI-FLEX, which has the potential to further enhance ficerafusp alfa’s profile. With our commercial leadership team now in place, we are well-positioned as we continue to prepare to bring ficerafusp alfa to patients.”
Third Quarter 2026 Highlights and Recent Progress
Ficerafusp Alfa in 1L R/M HPV-Negative HNSCC
- Achieved substantial enrollment in the FORTIFI-HN01 pivotal trial in first-line (1L) recurrent or metastatic (R/M) human papillomavirus (HPV)-negative head and neck squamous cell carcinoma (HNSCC), to enable topline results from an interim analysis in mid-2027.
- Continue to enroll FORTIFI-FLEX, a randomized, open-label clinical trial that is evaluating ficerafusp alfa, administered as a 12-week loading dose of 1500mg weekly (QW) followed by maintenance dosing of 2250mg every three weeks (Q3W) as compared to 1500mg QW of ficerafusp alfa, each in combination with pembrolizumab. The company expects to have results from this study by the time of a potential U.S. approval in 1L R/M HPV-negative HNSCC.
Key Anticipated Upcoming Milestones
HNSCC
- Expect topline results from an interim analysis of the FORTIFI-HN01 pivotal trial in 1L R/M HPV-negative HNSCC in mid-2027.
Other Solid Tumors and Translational Data
- Present data from Phase 1b expansion cohort evaluating ficerafusp alfa both as monotherapy and in combination with pembrolizumab in patients with 3L+ mCRC (RAS/BRAF wild type MSS) in January 2027.
- Present preclinical data evaluating the effect of tumor-targeted TGF-β neutralization with ficerafusp alfa on fibrosis and drug penetration at the European Society for Medical Oncology (ESMO) Immuno-Oncology & Advanced Therapies Congress 2026, taking place December 14-16 in London, United Kingdom.
Third Quarter 2026 Financial Results
- Cash, Cash Equivalents and Marketable Securities: As of September 30, 2026, Bicara had cash, cash equivalents and marketable securities of
$442.3 million , compared to$414.8 million in cash, cash equivalents and marketable securities as of December 31, 2025. Based on its current operating and development plans, the company expects that its existing cash, cash equivalents and marketable securities will fund operations into the first half of 2029. - Research and Development Expenses: Research and development expenses were
$56.5 million for the third quarter of 2026 as compared to$33.0 million for the third quarter of 2025. The increase was primarily due to costs associated with the ongoing FORTIFI-HN01 pivotal trial, FORTIFI-FLEX trial, Phase 1/1b dose expansion cohorts, and an increase in personnel costs. - General and Administrative Expenses: General and administrative expenses were
$19.2 million for the third quarter of 2026 as compared to$7.7 million for the third quarter of 2025. The increase was primarily due to additional personnel costs and professional fees associated with expanding the organization as the company advances its pivotal trial and prepares for potential commercialization. - Net Loss: Net loss totaled
$71.2 million for the third quarter of 2026 compared to$36.3 million for the third quarter of 2025.
Upcoming Investor Conferences
Bicara will participate in the following upcoming investor conferences:
- Stifel Healthcare Conference 2026 on November 11 at 9:20 a.m. ET
- Jefferies Global Healthcare Conference on November 16 at 12:00 p.m. GMT
- Piper Sandler 38th Annual Healthcare Conference on December 2 at 8:30 a.m. ET
Live webcasts of the fireside chats will be accessible through the Investor Relations section of Bicara’s website under Events and Presentations. Replays of the webcasts will be archived and available for 30 days following each event.
Conference Call Information
Bicara will host a live conference call and webcast at 8:30 a.m. ET today to discuss third quarter 2026 financial results and business updates. Individuals may register for the conference call by clicking the link here. Once registered, participants will receive dial-in details and a unique PIN that will allow them to access the call. An audio webcast will be accessible through the Investor Relations section of Bicara’s website under Events and Presentations. An archived replay will also be available for 30 days following the event.
About Bicara Therapeutics
Bicara is a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors. Bicara has built a platform designed to facilitate the development of bifunctional therapies that precisely target the tumor and deliver a tumor-modulating payload to the tumor site. This approach was deployed in the development of Bicara’s lead program ficerafusp alfa, a bifunctional epidermal growth factor receptor (EGFR) directed monoclonal antibody bound to a human transforming growth factor beta (TGF-β) ligand trap. By combining these two clinically validated targets, ficerafusp alfa has the potential to exert potent anti-tumor activity by simultaneously blocking both cancer cell-intrinsic EGFR survival and proliferation, as well as the immunosuppressive TGF-β signaling within the tumor microenvironment (TME). Ficerafusp alfa directs the TGF-β inhibitor into the immediate TME through the binding of EGFR on tumor cells, which Bicara believes will lead to deep and durable responses and an increase in overall survival, while reducing the potential adverse effects previously associated with systemic TGF-β inhibition. Ficerafusp alfa is being developed in head and neck squamous cell carcinoma, where there remains a significant unmet need, as well as other solid tumor types. For more information, please visit www.bicara.com or follow us on LinkedIn and X.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. These statements may be identified by words such as “may,” “might,” “will,” “could,” “would,” “should,” “plan,” “anticipate,” “intend,” “believe,” “expect,” “estimate,” “seek,” “predict,” “future,” “project,” “potential,” “continue,” “target” and similar words or expressions, or the negative thereof, are intended to identify forward-looking statements, although not all contain identifying words. Any statements in this press release that are not statements of historical fact may be deemed to be forward-looking statements. These forward-looking statements include, without limitation, express or implied statements regarding Bicara’s strategy, business plans and focus, including the clinical development of ficerafusp alfa, including the FORTIFI-HN01 pivotal trial interim analysis readout in mid-2027, the FORTIFI-FLEX study to evaluate a loading and Q3W maintenance regimen with anticipated results by the time of a potential U.S. approval in 1L R/M HPV-negative HNSCC, and the expansion cohorts of Bicara’s Phase 1/1b trial of ficerafusp alfa and the timing of future data releases; the growing recognition among investigators of the distinct biology of HPV-negative HNSCC; the expected therapeutic potential and clinical benefits of ficerafusp alfa, including potential efficacy, depth, durability and tolerability; Bicara’s ability to scale and prepare for potential commercialization of ficerafusp alfa; the potential for U.S. regulatory approval and launch of ficerafusp alfa, including our aim for ficerafusp alfa to enter the market with a competitive profile; and Bicara’s expected operating expenses and capital expenditure requirements, including its cash runway into the first half of 2029. Any forward-looking statements in this press release are based on management's current expectations and beliefs and are subject to a number of risks and uncertainties that are difficult to predict. Factors that could cause actual results to differ include, but are not limited to, risks relating to Bicara’s research and development activities; Bicara’s ability to execute on its business plans and strategy, including obtaining the requisite regulatory approvals on the expected timeline, if at all; uncertainties relating to the clinical development of ficerafusp alfa; the company’s dependence on third parties; risks related to the company’s financial condition and need for additional funds in order to commercialize ficerafusp alfa, if approved; risks related to regulatory developments and approval processes of the U.S. Food and Drug Administration and comparable foreign regulatory authorities; risks related to establishing and maintaining Bicara’s intellectual property protections; and risks related to the competitive landscape for ficerafusp alfa; as well as other risks described in “Risk Factors,” in Bicara’s most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q, as well as discussions of potential risks, uncertainties, and other important factors in Bicara’s subsequent filings with the U.S. Securities and Exchange Commission (SEC). In addition, any forward-looking statements represent Bicara’s views only as of today and should not be relied upon as representing its views as of any subsequent date. Bicara explicitly disclaims any obligation to update any forward-looking statements. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements.
Bicara intends to use its Investor Relations website as a means of disclosing material nonpublic information and for complying with its disclosure obligations under Regulation FD. Accordingly, investors should monitor the company’s Investor Relations website, in addition to following the company’s press releases, SEC filings, public conference calls, presentations, and webcasts.
| BICARA THERAPEUTICS INC. CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (Unaudited, in thousands except shares and per share data) | |||||||||||||||
| Three Months Ended September 30, | Nine Months EndedSeptember 30, | ||||||||||||||
| 2026 | 2025 | 2026 | 2025 | ||||||||||||
| Operating expenses | |||||||||||||||
| Research and development | $ | 56,476 | $ | 32,975 | $ | 149,713 | $ | 92,106 | |||||||
| General and administrative | 19,235 | 7,701 | 46,190 | 22,376 | |||||||||||
| Total operating expenses1 | 75,711 | 40,676 | 195,903 | 114,482 | |||||||||||
| Loss from operations | (75,711 | ) | (40,676 | ) | (195,903 | ) | (114,482 | ) | |||||||
| Other income | |||||||||||||||
| Interest income | 4,516 | 4,386 | 13,175 | 14,082 | |||||||||||
| Total other income | 4,516 | 4,386 | 13,175 | 14,082 | |||||||||||
| Net loss before income taxes | (71,195 | ) | (36,290 | ) | (182,728 | ) | (100,400 | ) | |||||||
| Income tax expense | (54 | ) | (40 | ) | (168 | ) | (164 | ) | |||||||
| Net loss | $ | (71,249 | ) | $ | (36,330 | ) | $ | (182,896 | ) | $ | (100,564 | ) | |||
| Net Loss per share, basic and diluted | $ | (1.04 | ) | $ | (0.67 | ) | $ | (2.78 | ) | $ | (1.84 | ) | |||
| Weighted-average number common shares outstanding, basic and diluted | 68,375,411 | 54,563,864 | 65,717,625 | 54,519,496 | |||||||||||
| Other comprehensive loss | |||||||||||||||
| Unrealized loss on marketable securities, net of tax | (1,301 | ) | (136 | ) | (2,112 | ) | (136 | ) | |||||||
| Total other comprehensive loss | (1,301 | ) | (136 | ) | (2,112 | ) | (136 | ) | |||||||
| Total comprehensive loss | $ | (72,550 | ) | $ | (36,466 | ) | $ | (185,008 | ) | $ | (100,700 | ) | |||
| 1Expenses include the following non-cash stock-based compensation expense | |||||||||||||||
| Research & Development | $ | 2,911 | $ | 1,384 | $ | 9,362 | $ | 3,684 | |||||||
| General and administrative | 7,069 | 2,230 | 14,714 | 6,873 | |||||||||||
| Total stock-based compensation expense | $ | 9,980 | $ | 3,614 | $ | 24,076 | $ | 10,557 | |||||||
| BICARA THERAPEUTICS INC. CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited, in thousands) | |||||
| September 30, 2026 | December 31, 2025 | ||||
| Assets | |||||
| Current assets | |||||
| Cash and cash equivalents | $ | 82,021 | $ | 96,685 | |
| Prepaid expenses and other assets | 9,064 | 7,252 | |||
| Marketable securities | 360,325 | 318,116 | |||
| Total current assets | 451,410 | 422,053 | |||
| Property and equipment, net | 965 | 330 | |||
| Right of use asset – operating lease | 723 | 1,701 | |||
| Other assets | 7,544 | 6,910 | |||
| Total assets | $ | 460,642 | $ | 430,994 | |
| Liabilities and stockholders’ equity | |||||
| Current liabilities | |||||
| Accounts payable | $ | 2,979 | $ | 5,515 | |
| Accounts payable – related party | 658 | 2,278 | |||
| Accrued expenses and other current liabilities | 46,184 | 18,898 | |||
| Accrued expenses and other current liabilities – related party | 530 | 1,141 | |||
| Operating lease liability – current portion | 880 | 1,117 | |||
| Total current liabilities | 51,231 | 28,949 | |||
| Operating lease liability – net of current portion | – | 593 | |||
| Total liabilities | 51,231 | 29,542 | |||
| Total stockholders' equity | 409,411 | 401,452 | |||
| Total liabilities and stockholders’ equity | $ | 460,642 | $ | 430,994 | |
Contacts
Investors
Rachel Frank
IR@bicara.com
Media
Tim Palmer
Tim.Palmer@bicara.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
When does Bicara expect results from the FORTIFI-HN01 pivotal trial?
Bicara expects topline results from the FORTIFI-HN01 interim analysis in mid-2027. The trial has achieved substantial enrollment in first-line recurrent or metastatic HPV-negative head and neck squamous cell carcinoma.
How long does Bicara expect its cash to fund operations?
Bicara expects its existing cash, cash equivalents and marketable securities to fund operations into the first half of 2029, based on current operating and development plans. Those holdings totaled $442.3 million as of September 30, 2026.
What dosing schedules is Bicara testing in FORTIFI-FLEX?
FORTIFI-FLEX compares 12 weeks of 1500 mg weekly followed by 2250 mg every three weeks with continued 1500 mg weekly dosing of ficerafusp alfa. Both groups also receive pembrolizumab. The study is randomized and open-label, meaning treatment assignments are known.
Which colorectal cancer patients are included in Bicara's planned January 2027 data presentation?
The Phase 1b expansion cohort evaluates ficerafusp alfa alone and with pembrolizumab in patients receiving third-line or later treatment for metastatic colorectal cancer. The specified population has RAS/BRAF wild-type, microsatellite-stable disease.